argenx to Present at Upcoming Investor Conferences
ARGXAugust 28, 2025
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in September:
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
ARGXAugust 25, 2025, 7:00 AM CET
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
ARGXAugust 19, 2025
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled “R&D Spotlight | Pioneering MuSK Biology with ARGX-119” on Tuesday, September 16, 2025, at 2:00pm ET.
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
ARGXSeles speaks out about her diagnosis with MG, a chronic autoimmune disease that causes muscle weakness, which can be severe and significantly impact daily life
Wedbush Reiterates Outperform on argenx, Maintains $715 Price Target
ARGXHC Wainwright & Co. Reiterates Buy on argenx, Maintains $720 Price Target
ARGXargenx SE To Present Results From Phase 2 Studies Evaluating VYVGART In Sjogren's Disease And Idiopathic Inflammatory Myopathies At EULAR 2025; Co. Announces That The U.S FDA Has Granted Efgartigimod Fast Track Designation For The Treatment Of Primary Sj
ARGXHC Wainwright & Co. Reiterates Buy on argenx, Maintains $720 Price Target
ARGX$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
ARGXWith Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?
ARGXHC Wainwright upgrades Kyverna to Buy with a $5 target, citing upcoming trial data and a strong cash position that supports a runway into 2027.
Baird Upgrades argenx to Outperform, Maintains Price Target to $680
ARGXIf You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
ARGX14 Analysts Have This To Say About argenx
ARGXOppenheimer Maintains Outperform on argenx, Raises Price Target to $708
ARGXGuggenheim Maintains Buy on argenx, Lowers Price Target to $1065
ARGXCitigroup Maintains Buy on argenx, Raises Price Target to $803
ARGXargenx Maintains FY25 Financial Guidance With $2.5B Target For Combined SG&A And R&D Expenses
ARGXargenx Q1 EPS $2.58 Beats $2.25 Estimate, Sales $807.31M Beat $795.84M Estimate
ARGXA Look Into argenx Inc's Price Over Earnings
ARGXP/E Ratio Insights for argenx
ARGXargenx's VYVGART For CIDP Gains Positive CHMP Opinion Based On Data From ADHERE Clinical Trial
ARGX$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
ARGXWhat's Driving the Market Sentiment Around argenx?
ARGXHere's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
ARGXCitigroup Maintains Buy on argenx, Raises Price Target to $796
ARGXWedbush Reiterates Outperform on argenx, Maintains $715 Price Target
ARGXFDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting
ARGXFDA approves Argenx's Vyvgart Hytrulo prefilled syringe for self-injection in gMG and CIDP, offering flexible dosing and expanding treatment options.
Wedbush Reiterates Outperform on argenx, Maintains $715 Price Target
ARGXWhat 11 Analyst Ratings Have To Say About argenx
ARGXHC Wainwright & Co. Reiterates Buy on argenx, Maintains $720 Price Target
ARGXargenx SE Receives FDA Approval Of VYVGART Hytrulo Prefilled Syringe For Self-Injection In Generalized Myasthenia Gravis And Chronic Inflammatory Demyelinating Polyneuropathy
ARGXPharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
ARGXTrump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.
HC Wainwright & Co. Reiterates Buy on argenx, Maintains $720 Price Target
ARGXArgenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients
ARGXArgenx reports long-term Vyvgart data showing lasting efficacy in gMG and CIDP, with strong safety and symptom control across multiple studies.
argenx Advances Neuromuscular Pipeline With First-in-Human ARGX-119 Data And Ongoing Label Expansion For Ocular And Seronegative MG
ARGXHere's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
ARGXLooking Into argenx's Recent Short Interest
ARGXP/E Ratio Insights for argenx
ARGXGuggenheim Maintains Buy on argenx, Raises Price Target to $1100
ARGXArgenx to Present New Data on VYVGART's Long-Term Benefits for Autoimmune Patients at AAN Annual Meeting
ARGXWhat Analysts Are Saying About argenx Stock
ARGXIf You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
ARGXBaird Maintains Neutral on argenx, Raises Price Target to $680
ARGXOppenheimer Maintains Outperform on argenx, Raises Price Target to $704
ARGXWells Fargo Maintains Overweight on argenx, Raises Price Target to $741
ARGXCitizens Capital Markets Maintains Outperform on argenx, Raises Price Target to $701
ARGXHC Wainwright & Co. Maintains Buy on argenx, Raises Price Target to $720
ARGXargenx Q4 2024 GAAP EPS $11.79 Up From $(1.68) YoY, Sales $761.22M Beat $706.28M Estimate
ARGX$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
ARGXHC Wainwright & Co. Reiterates Buy on argenx, Raises Price Target to $717
ARGX